Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth - PubMed (original) (raw)
Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth
P Lin et al. J Clin Invest. 1997.
Abstract
Tie2 is a novel receptor tyrosine kinase that is expressed almost exclusively by vascular endothelium. Disruption of Tie2 function in transgenic mice resulted in embryonic lethality secondary to characteristic vascular defects; similar defects occurred after disruption of the Tie2 ligand. These findings indicate that the Tie2/Tie2 ligand pathway plays important roles during development of the embryonic vasculature. To determine whether the Tie2 pathway was involved in pathologic angiogenesis in adult tissues, a soluble form of the extracellular domain of murine Tie2 (ExTek.6His) was developed and used as a Tie2 inhibitor. After a single application of the ExTek.6His protein into a rat cutaneous window chamber, growth of a mammary tumor inside the chamber was reduced by > 75% (P < 0.005), and tumor vascular length density was reduced by 40% when compared with control-treated tumors (P < 0.01). In the rat cornea, ExTek.6His blocked angiogenesis stimulated by tumor cell conditioned media. ExTek.6His protein did not affect the viability of cultured tumor cells, indicating that the antitumor effect of ExTek.6His was due to the inhibition of tumor angiogenesis. These data demonstrate a role for the Tie2 pathway in pathologic angiogenesis, suggesting that targeting this pathway may yield effective antiangiogenic agents for treatment of cancer and other angiogenic diseases.
Similar articles
- Functional significance of Tie2 signaling in the adult vasculature.
Peters KG, Kontos CD, Lin PC, Wong AL, Rao P, Huang L, Dewhirst MW, Sankar S. Peters KG, et al. Recent Prog Horm Res. 2004;59:51-71. doi: 10.1210/rp.59.1.51. Recent Prog Horm Res. 2004. PMID: 14749497 Review. - Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor.
Lin P, Sankar S, Shan S, Dewhirst MW, Polverini PJ, Quinn TQ, Peters KG. Lin P, et al. Cell Growth Differ. 1998 Jan;9(1):49-58. Cell Growth Differ. 1998. PMID: 9438388 - Responses of vascular endothelial cells to angiogenic signaling are important for tumor cell survival.
Shan S, Robson ND, Cao Y, Qiao T, Li CY, Kontos CD, Garcia-Blanco M, Dewhirst MW. Shan S, et al. FASEB J. 2004 Feb;18(2):326-8. doi: 10.1096/fj.03-0765fje. Epub 2003 Dec 19. FASEB J. 2004. PMID: 14688196 - Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2.
Lin P, Buxton JA, Acheson A, Radziejewski C, Maisonpierre PC, Yancopoulos GD, Channon KM, Hale LP, Dewhirst MW, George SE, Peters KG. Lin P, et al. Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8829-34. doi: 10.1073/pnas.95.15.8829. Proc Natl Acad Sci U S A. 1998. PMID: 9671764 Free PMC article. - Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN, Meshram RJ. Gacche RN, et al. Prog Biophys Mol Biol. 2013 Nov;113(2):333-54. doi: 10.1016/j.pbiomolbio.2013.10.001. Epub 2013 Oct 15. Prog Biophys Mol Biol. 2013. PMID: 24139944 Review.
Cited by
- Minimally invasive colorectal resection for cancer is associated with a short-lived decrease in soluble Tie-2 receptor levels, which may transiently inhibit VEGF-mediated angiogenesis (via altered blood levels of free Ang-1 and Ang-2).
Shantha Kumara HM, Grieco MJ, Yan X, Kalady MF, DiMaggio V, Kim DG, Hyman N, Feingold DL, Whelan RL. Shantha Kumara HM, et al. Surg Endosc. 2010 Oct;24(10):2581-7. doi: 10.1007/s00464-010-1008-z. Epub 2010 Mar 31. Surg Endosc. 2010. PMID: 20354881 - Dysregulation of the angiopoietin-Tie-2 axis in sepsis and ARDS.
Parikh SM. Parikh SM. Virulence. 2013 Aug 15;4(6):517-24. doi: 10.4161/viru.24906. Epub 2013 May 7. Virulence. 2013. PMID: 23652985 Free PMC article. Review. - The use of reverse immunology to identify HLA-A2 binding epitopes in Tie-2.
Ramage JM, Spendlove I, Rees R, Moss RS, Durrant LG. Ramage JM, et al. Cancer Immunol Immunother. 2006 Aug;55(8):1004-10. doi: 10.1007/s00262-005-0119-1. Epub 2006 Jan 12. Cancer Immunol Immunother. 2006. PMID: 16408213 Free PMC article. - Anti-angiogenic properties of a sulindac analogue.
Pyriochou A, Tsigkos S, Vassilakopoulos T, Cottin T, Zhou Z, Gourzoulidou E, Roussos C, Waldmann H, Giannis A, Papapetropoulos A. Pyriochou A, et al. Br J Pharmacol. 2007 Dec;152(8):1207-14. doi: 10.1038/sj.bjp.0707534. Epub 2007 Oct 29. Br J Pharmacol. 2007. PMID: 17965739 Free PMC article. - Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo.
Jendreyko N, Popkov M, Rader C, Barbas CF 3rd. Jendreyko N, et al. Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8293-8. doi: 10.1073/pnas.0503168102. Epub 2005 May 31. Proc Natl Acad Sci U S A. 2005. PMID: 15928093 Free PMC article.
References
- Nature. 1994 Feb 10;367(6463):576-9 - PubMed
- J Leukoc Biol. 1994 Mar;55(3):410-22 - PubMed
- J Natl Cancer Inst. 1994 Apr 20;86(8):635-6 - PubMed
- Development. 1993 Nov;119(3):957-68 - PubMed
- Ann Plast Surg. 1994 Jun;32(6):588-94 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous